Systemic Lupus Erythematous SLE Drugs Market

Systemic Lupus Erythematous SLE Drugs Market Overview

The systemic lupus erythematosus (SLE) drugs market is projected to record a CAGR of 5% during the forecast period, up from US$ 183.3 Bn in 2020, to reach a valuation of US$ 329.18 Bn by 2032.

The systemic lupus erythematosus (SLE) drugs market is anticipated to show promising growth prospects owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).

Sales of systemic lupus erythematosus (SLE) drugs is expected to rise with the introduction of novel biological therapies in the development pipeline. In addition to this, demand for systemic lupus erythematosus (SLE) drugs is rising due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE).

This factor is anticipated to significantly influence the systemic lupus erythematosus (SLE) drugs market, as over 50% of SLE patients have lupus nephritis. 

Some new potential medications in Phase III studies are also projected to contribute to the growth of the systemic lupus erythematosus (SLE) drugs market share.

Some of the key systemic lupus erythematosus (SLE) drugs trends promoting the demand for systemic lupus erythematosus (SLE) drugs market include clinicians only administering biologics when two or more non-biologic immunosuppressants have failed to ameliorate a patient's disease activity.

Several nations have developed payment schemes based on these criteria, which greatly boosted the sales of systemic lupus erythematosus (SLE) drugs. 

In developed nations, demand for systemic lupus erythematosus (SLE) drugs is higher due to stronger healthcare infrastructure and coverage availability. In underdeveloped regions, high costs and a lack of government-funded coverage limit access to biologics.

What are the Key Contributors to the Systemic Lupus Erythematosus (SLE) Drugs Market Share?

The global market for systemic lupus erythematosus (SLE) drugs is expected to expand due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE). The development of newer SLE medicines increased availability of biosimilar pharmaceuticals, and increased support for developing research areas for new drug molecules are increasing the sales of systemic lupus erythematosus (SLE) drugs and propelling the global systemic lupus erythematosus (SLE) drugs market forward. 

Increased awareness of illness diagnosis and treatment and constant research and development procedures for innovative therapeutic molecules are major drivers of the global systemic lupus erythematosus (SLE) drugs. Furthermore, the safety and quality of systemic lupus erythematous controlling therapy may provide a hurdle to the sales of systemic lupus erythematosus (SLE) drugs. 

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Region holds the Highest Growth Potential in the Systemic Lupus Erythematosus (SLE) Drugs Market?

Global systemic lupus erythematosus (SLE) drugs market growth is fast in the North American region and is estimated to project remarkable CAGR growth throughout the forecast period.

In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans, according to the Centers for Disease Control and Prevention (CDC). It is anticipated that this factor will boost the demand for systemic lupus erythematosus (SLE) drugs in the region.

The second-largest and fastest-growing systemic lupus erythematosus (SLE) drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double-digit CAGR due to the higher prevalence of SLE in Europe. According to the Lupus Journal article, among the European countries, Sweden, Iceland, and Spain recorded the highest sales of systemic lupus erythematosus (SLE) drugs.

This is expected to be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy, Spain, the UK and Japan. Benlysta will lead sales of systemic lupus erythematosus (SLE) drugs in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. 

Who are the Key Players in the Systemic Lupus Erythematosus (SLE) Drugs Market?

The key players in the global systemic lupus erythematous drugs market are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

Recent Developments

• Hydroxychloroquine, the last drug, was approved by the FDA in 1955 for SLE treatment. 
• Recently, a drug called belimumab was approved by FDA after 50 years long gap specifically for SLE, on March 9, 2011. It is the first-ever targeted biological drug for the treatment of SLE patients developed by Human Genome Sciences Inc. 
• In collaboration with GlaxoSmithKline, Benlysta is anticipated to lead systemic lupus erythematosus (SLE) drugs market sales in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. 
• NSAIDs such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE.

Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Scope of Report